154 related articles for article (PubMed ID: 37700916)
21. The corpus cavernosum after treatment with dutasteride or finasteride: A histomorphometric study in a benign prostatic hyperplasia rodent model.
Da Silva MHA; Costa WS; B Sampaio FJ; De Souza DB
Asian J Androl; 2018; 20(5):505-510. PubMed ID: 29893293
[TBL] [Abstract][Full Text] [Related]
22. [Add-on effect of dutasteride in patients with benign prostatic hyperplasia treated with alpha blocker : its effect on overactive bladder].
Wada N; Hashidume K; Tamaki G; Kita M; Iwata T; Matsumoto S; Kakizaki H
Hinyokika Kiyo; 2012 Sep; 58(9):475-80. PubMed ID: 23070385
[TBL] [Abstract][Full Text] [Related]
23. Update on the use of dutasteride in the management of benign prostatic hypertrophy.
Miller J; Tarter TH
Clin Interv Aging; 2007; 2(1):99-104. PubMed ID: 18044081
[TBL] [Abstract][Full Text] [Related]
24. Dutasteride: a dual 5-alpha reductase inhibitor for the treatment of symptomatic benign prostatic hyperplasia.
Dolder CR
Ann Pharmacother; 2006 Apr; 40(4):658-65. PubMed ID: 16569804
[TBL] [Abstract][Full Text] [Related]
25. Inhibitors of 5alpha-reductase in the treatment of benign prostatic hyperplasia.
Tarter TH; Vaughan ED
Curr Pharm Des; 2006; 12(7):775-83. PubMed ID: 16515494
[TBL] [Abstract][Full Text] [Related]
26. Effect of the dual 5alpha-reductase inhibitor, dutasteride, on serum testosterone and body mass index in men with benign prostatic hyperplasia.
Hong SK; Min GE; Ha SB; Doo SH; Kang MY; Park HJ; Yoon CY; Jeong SJ; Byun SS; Lee SE
BJU Int; 2010 Apr; 105(7):970-4. PubMed ID: 19793378
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of Adding Dutasteride to α-Blocker Therapy Treated Benign Prostatic Hyperplasia Patients with Small Volume Prostate (<30 mL).
Hashimoto M; Shimizu N; Sugimoto K; Hongoh S; Minami T; Nozawa M; Yoshimura K; Hirayama A; Tahara H; Uemura H
Low Urin Tract Symptoms; 2017 Sep; 9(3):157-160. PubMed ID: 26991643
[TBL] [Abstract][Full Text] [Related]
28. Effects of dutasteride on serum free-testosterone and clinical significance of testosterone changes.
Enatsu N; Miyake H; Haraguchi T; Chiba K; Fujisawa M
Andrologia; 2016 Dec; 48(10):1195-1201. PubMed ID: 26952737
[TBL] [Abstract][Full Text] [Related]
29. Relationship among serum testosterone, sexual function, and response to treatment in men receiving dutasteride for benign prostatic hyperplasia.
Marberger M; Roehrborn CG; Marks LS; Wilson T; Rittmaster RS
J Clin Endocrinol Metab; 2006 Apr; 91(4):1323-8. PubMed ID: 16434455
[TBL] [Abstract][Full Text] [Related]
30. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 4-year data from the CombAT study.
Montorsi F; Henkel T; Geboers A; Mirone V; Arrosagaray P; Morrill B; Black L
Int J Clin Pract; 2010 Jul; 64(8):1042-51. PubMed ID: 20487046
[TBL] [Abstract][Full Text] [Related]
31. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor.
Clark RV; Hermann DJ; Cunningham GR; Wilson TH; Morrill BB; Hobbs S
J Clin Endocrinol Metab; 2004 May; 89(5):2179-84. PubMed ID: 15126539
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of sexual function after dutasteride treatment in patients with once-negative prostate biopsy and benign prostate hyperplasia.
Taniguchi H; Inoue T; Kawa G; Murota T; Tsukino H; Yoshimura K; Kamoto T; Ogawa O; Matsuda T; Kinoshita H
Urologia; 2023 May; 90(2):295-300. PubMed ID: 36992564
[TBL] [Abstract][Full Text] [Related]
33. Dutasteride/tamsulosin: in benign prostatic hyperplasia.
Keating GM
Drugs Aging; 2012 May; 29(5):405-19. PubMed ID: 22550968
[TBL] [Abstract][Full Text] [Related]
34. Meta-analysis of the efficacy and safety of combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia.
Zhou Z; Cui Y; Wu J; Ding R; Cai T; Gao Z
BMC Urol; 2019 Mar; 19(1):17. PubMed ID: 30871552
[TBL] [Abstract][Full Text] [Related]
35. [Dutasteride: main results in the treatment of benign prostatic hyperplasia].
Le-Coent R
Ann Urol (Paris); 2004 Dec; 38 Suppl 2():S62-6. PubMed ID: 15651494
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia.
Debruyne F; Barkin J; van Erps P; Reis M; Tammela TL; Roehrborn C;
Eur Urol; 2004 Oct; 46(4):488-94; discussion 495. PubMed ID: 15363566
[TBL] [Abstract][Full Text] [Related]
37. Impact of early vs. delayed initiation of dutasteride/tamsulosin combination therapy on the risk of acute urinary retention or BPH-related surgery in LUTS/BPH patients with moderate-to-severe symptoms at risk of disease progression.
D'Agate S; Chavan C; Manyak M; Palacios-Moreno JM; Oelke M; Michel MC; Roehrborn CG; Della Pasqua O
World J Urol; 2021 Jul; 39(7):2635-2643. PubMed ID: 33337513
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and Safety of Dutasteride in Chinese Adults with Symptomatic Benign Prostatic Hyperplasia : A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study with an Open-Label Extension.
Na Y; Ye Z; Zhang S
Clin Drug Investig; 2012 Jan; 32(1):29-39. PubMed ID: 27933597
[TBL] [Abstract][Full Text] [Related]
39. A cost effective analysis of fixed-dose combination of dutasteride and tamsulosin compared with dutasteride monotherapy for benign prostatic hyperplasia in Nigeria: a middle income perspective; using an interactive Markov model.
Udeh EI; Ofoha CG; Adewole DA; Nnabugwu II
BMC Cancer; 2016 Jul; 16():405. PubMed ID: 27388750
[TBL] [Abstract][Full Text] [Related]
40. Impact of disease progression on individual IPSS trajectories and consequences of immediate versus delayed start of treatment in patients with moderate or severe LUTS associated with BPH.
D'Agate S; Wilson T; Adalig B; Manyak M; Palacios-Moreno JM; Chavan C; Oelke M; Roehrborn C; Della Pasqua O
World J Urol; 2020 Feb; 38(2):463-472. PubMed ID: 31079189
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
